Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
OLMA - Olema Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$40.33
DETAILS
HIGH:
$48.00
LOW:
$35.00
MEDIAN:
$38.00
CONSENSUS:
$40.33
UPSIDE:
264.32%
Stock News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 176,150 shares of the Company's common stock, effective as of June 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026 First clinical collaboration for OP-3136; results to inform combination strategy in metastatic prostate cancer setting SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced a clinical trial collaboration and supply agreement with Bayer AG (“Bayer”) to evaluate OP-3136, Olema's investigational lysine acetyltransferase 6 (KAT6) inhibitor, in combination with NUBEQA® (darolutamide), Bayer's androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC). The Phase 1b/2 study is designed to assess the safety, tolerability, and preliminary anti-tumor activity of OP-3136 in combination with darolutamide in approximately 36 patients with mCRPC.
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across multiple solid tumor types Data support the ongoing Phase 1 evaluation of OP-3136 as a monotherapy and in combination with fulvestrant and palazestrant SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preliminary clinical data from the Phase 1 study of OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor. The data will be presented in a poster presentation on May 30, 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois.
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 7 th Annual Oncology Innovation Summit Date and Time: May 26, 2026 at 12:30 p.m. ETFormat: Fireside ChatLocation: Virtual Jefferies Global Healthcare Conference Date and Time: June 3, 2026 at 8:45 a.m.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to five new employees to purchase an aggregate of 154,700 shares of the Company's common stock, effective as of May 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Prakash Raman, Ph.D., to its Board of Directors.
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
SAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present initial clinical data from the Phase 1 study of OP-3136 in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29-June 2 in Chicago, Illinois. The Company will also present a trial-in-progress poster for the Phase 3 OPERA-02 trial.
Analyzing Olema Pharmaceuticals (NASDAQ:OLMA) and Ligand Pharmaceuticals (NASDAQ:LGND)
Olema Pharmaceuticals (NASDAQ: OLMA - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership. Earnings and Valuation This table compares Olema Pharmaceuticals
SG Americas Securities LLC Purchases Shares of 69,382 Olema Pharmaceuticals, Inc. $OLMA
SG Americas Securities LLC bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 69,382 shares of the company's stock, valued at approximately $1,735,000. SG Americas Securities
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 188,500 shares of the Company's common stock, effective as of April 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?
Paradigm Biocapital Advisor increased its stake in Olema Pharmaceuticals by 750,000 shares in Q4 2025. The quarter-end value of the position rose by $122.09 million, reflecting the new purchase.
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Olema Pharmaceuticals (OLMA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter. The value of the position was $68.75 million at quarter-end.
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-02 pivotal Phase 3 trial of palazestrant in combination with ribociclib in patients with frontline ER+/HER2- metastatic breast cancer Initiated the Phase 1b/2 study of palazestrant in combination with Pfizer's novel CDK4 inhibitor, atirmociclib, in patients with ER+/HER2- metastatic breast cancer Continued enrollment in the Phase 1 clinical study of OP-3136 in breast cancer and other solid tumors, with initial clinical data expected in Q2 2026 Generated $218.5 million in gross proceeds from a follow-on public offering, further strengthening the Company's balance sheet; ended 2025 with $505.4 million in cash, cash equivalents, and marketable securities Transformation into a fully-integrated oncology company underway in preparation for the Company's first potential commercial launch in late 2027 SAN FRANCISCO, March 16, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the fourth quarter and full year ended December 31, 2025. “2025 was a year of strong execution across the business as we advanced palazestrant as a differentiated endocrine therapy across multiple regimens, highlighted by continued enrollment and strong investigator interest in our OPERA-01 and OPERA-02 trials,” said Sean P.
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA
LOS ANGELES--(BUSINESS WIRE)--Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA.
Why Is Olema Pharmaceuticals Stock Dropping On Monday?
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) stock is trading lower on Monday, in reaction to data from Roche Holdings AG's (OTC: RHHBY) phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 205,000 shares of the Company's common stock, effective as of March 2, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit
Olema Pharmaceuticals (NASDAQ: OLMA) is focused on developing endocrine therapies aimed at improving outcomes for patients with estrogen receptor (ER)-positive, HER2-negative breast cancer, CEO Sean Bohen said during a company discussion hosted by Brad Canino. Bohen described the disease area as a large unmet need, noting that breast cancer is the most common cancer diagnosis in
Price Targets
Olema Oncology price target lowered to $35 from $38 at Guggenheim
$35.00
(was $13.97)
Guggenheim
Olema Pharmaceuticals (OLMA) PT Lowered to $38 at H.C. Wainwright
$38.00
(was $16.45)
Emily Bodnar
·
H.C. Wainwright
Olema Oncology initiated with a Buy at Stifel
$48.00
(was $23.37)
Stifel Nicolaus
Olema Oncology initiated with an Overweight at Piper Sandler
$40.00
(was $25.04)
Piper Sandler
UBS Starts Olema Pharmaceuticals (OLMA) at Buy
$45.00
(was $25.04)
Michael Yee
·
UBS
Olema Oncology price target raised to $48 from $45 at Oppenheimer
$48.00
(was $31.66)
Oppenheimer
Olema Oncology price target raised to $38 from $26 at Goldman Sachs
$38.00
(was $30.68)
Goldman Sachs
Olema Pharmaceuticals (OLMA) PT Raised to $45 at H.C. Wainwright
$45.00
(was $32.22)
Emily Bodnar
·
H.C. Wainwright
Olema Oncology price target raised to $43 from $30 at Jefferies
$43.00
(was $30.66)
Michael Yee
·
Jefferies
Olema Oncology price target raised to $26 from $18 at Goldman Sachs
$26.00
(was $22.01)
Goldman Sachs
Olema Oncology price target raised to $40 from $20 at Guggenheim
$40.00
(was $22.16)
Guggenheim
Olema Oncology price target raised to $36 from $28 at H.C. Wainwright
$36.00
(was $20.14)
H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
$28.00
(was $9.36)
Emily Bodnar
·
H.C. Wainwright
Olema Oncology initiated with a Buy at Guggenheim
$20.00
(was $10.44)
Guggenheim
Goldman Sachs Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
$27.00
(was $11.91)
Richard Law
·
Goldman Sachs
Olema Pharmaceuticals (OLMA) PT Raised to $30 at H.C. Wainwright
$30.00
(was $9.85)
Emily Bodnar
·
H.C. Wainwright
Goldman Sachs Starts Olema Pharmaceuticals (OLMA ) at Buy, 'Best-in-Class Potential in Large BC Market'
$24.00
(was $10.89)
Richard Law
·
Goldman Sachs